ライフサイエンスコーパス: fish oil

1 nd the concurrent decline of global sources (fish oils).

2 was extended to allow parallel isolation of fish oil.

3 ls rich in SFA, unsaturated fat and SFA with fish oil.

4 racteristics than yogurt fortified with free fish oil.

5 rs of EPA/DHA and promising alternatives for fish oil.

6 influenced by encapsulation of quercetin or fish oil.

7 roplets and lower viscosity compared to neat fish oil.

8 p to 62% lower than other systems containing fish oil.

9 e oils a nutritional added value compared to fish oil.

10 nsaturated fatty acid (omega3 PUFA) enriched fish oil.

11 live oil, but not in those supplemented with fish oil.

12 oating to improve the oxidative stability of fish oil.

13 A)-rich Schizochytrium sp. as substitute for fish oil.

14 docosahexaenoic acid, a major constituent of fish oil.

15 lity than those supplemented with commercial fish oil.

16 g a control diet or a diet supplemented with fish oil.

17 rties and oxidative stability of spray-dried fish oil.

18 and EPA contents than yogurt containing free fish oil.

19 s there was no change in the identity of the fish oils.

20 c PAHs, as well as two EPA indicator PAHs in fish oils.

21 inexpensive source of omega-3's, compared to fish oils.

22 Patients were randomized to receive fish oil (1-g capsules containing >/=840 mg n-3-PUFAs as

23 + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days,

24 + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days,

25 -18.6+/-4.5 mOsmol/l; n = 18; P < 0.001) and fish oil (-19.8+/-3.9 mOsmol/l; n = 19; P < 0.001) suppl

26 ed fatty acids were the most concentrated in fish oils (25.3-30.8% and 36.1-45.0%).

27 Low-dose fish oil (3 capsules/day, 1080 mg eicosapentaenoic acid+

28 Patients were randomized to fish oil (4 g/day) or placebo and followed, on average,

29 based systems containing high percentage of fish oil (50%) were evaluated; and betaLg-polyCA present

30 e containing all animal fat and another with fish oil added directly.

31 In contrast, study results of fish oil administration in critically ill patients are c

32 de protein hydrolysate, were able to protect fish oil against oxidation in an iron induced oxidation

33 hiobarbituric acid tests showed that in bulk fish oil, all esters were more effective than alpha-toco

34 Nannochloropsis were compared to commercial fish oil and analyzed for their amount of n-3 LC-PUFA, l

35 uced, but not fully eliminated, fishmeal and fish oil and are seeking cost competitive replacements.

36 Instead, fish oil and fenofibrate reduced circulating and hepatic

37 er diabetic conditions and by lipid-lowering fish oil and fenofibrate.

38 for parallel cold production of high-quality fish oil and gel-forming proteins from fish by-products.

39 The bioavailability of the formulated fish oil and its inhibitory response against lipopolysac

40 allate, and alpha-tocopherol in a bulk Kilka fish oil and its oil-in-water emulsion stabilized by soy

41 of the current supplements of DHA, including fish oil and krill oil, do not significantly increase br

42 al intervention with extra protein, leucine, fish oil and oligosaccharides on cardiac and skeletal mu

43 VW-FO will address the increasing demand for fish oil and reduce pollution problems.

44 ants, to inhibit lipid oxidation in menhaden fish oil and structured lipid-based infant formula emuls

45 of oxidation in liposome model system and in fish oil and were high in phenolic content.

46 sing use of the deep ocean (e.g., for bottom fishing, oil and gas extraction, and deep-seabed mining)

47 d and milk was compared with unencapsulated (fish oil) and microencapsulated omega3 PUFAs.

48 cial effects of dietary supplementation with fish oils, and offer new avenues for developing therapeu

49 -3 LC-PUFA levels are equivalent to those in fish oils, and represent a sustainable, terrestrial sour

50 assigned as follows: 27 to vitamin D3; 20 to fish oil; and 22 to placebo.

51 Combination lipid emulsions containing fish oil are associated with decreased bilirubin levels,

52 more modest improvement was observed in the fish oil arm [5.9 (4.8, 7.0) to 5.2 (3.7, 6.8), P = 0.39

53 ndpoint occurred in 64.1% of patients in the fish oil arm and 63.2% of patients in the placebo arm (h

54 nd canola oil were evaluated as replacers of fish oil at three levels of inclusion (60%, 75% and 90%)

55 Fifty-one patients (81%) received a fish oil-based lipid emulsion (1 g/kg/d), 40 (63%) were

56 eview the most recent literature involving a fish oil-based lipid emulsion (FOLE) and its effects on

57 stability of omega-3 PUFAs concentrates from fish oil, biopolymer coating based on chitosan (CH) and

58 (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily)

59 270 mg/day eicosapentaenoic acid (EPA) from fish oil capsules or the placebo (olive oil capsules) fo

60 gleton pregnancy were provided with DHA-rich fish-oil capsules (800 mg DHA/d) or vegetable-oil capsul

61 iple fetuses were assigned to receive either fish-oil capsules that contained 900 mg of n-3 long-chai

62 Fish oil combined with milk fat, unlike unsaturated lipi

63 to high-fat meals containing EPA + DHA-rich fish oil compared with DHA-rich AO, but these difference

64 moisture content of beta-cyclodextrin/Danube fish oils complexes (common barbel, Pontic shad, Europea

65 All fish oils complied with a p-AV limit of 30, 98% with a P

66 with wrinkles was observed when the initial fish oil concentration was increased up to 50%.

67 With increasing initial fish oil concentration, melting point of the fish oil-lo

68 7.5%, w/w) was achieved at 50%, w/w, initial fish oil concentration.

69 PGE2 production decreases 50% when fish oil consumption produces tissue EPA/AA ratios of >/

70 etween fatty acids measured in late life and fish-oil consumption in early life, midlife, and late li

71 Daily fish-oil consumption in late life was associated with lo

72 Daily fish-oil consumption in midlife was associated with lowe

73 Fish-oil consumption was assessed by using validated que

74 ional analysis of triacylglycerols (TAGs) in fish oils containing eicosapentaenoic (EPA, 20:5) and do

75 ndations favor higher amino acid intakes and fish oil-containing lipid emulsions.

76 Fish oil contains a complex mixture of omega-3 fatty aci

77 The influence of fish oil content (50, 60 and 70%, w/w), amount of total

78 sity decreased significantly with decreasing fish oil content, whereas the ratio of CAS to PC did not

79 acid (FA) composition in the skin by dietary fish oil could provide therapeutic benefits.

80 at the low PAH contamination of the selected fish oils could mainly occur by atmospheric sources.

81 debridement (CG), omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) after periodonta

82 group [TG]1), or omega-3 PUFA + ASA (3 g of fish oil/d + 100 mg ASA/d for 2 months) before periodont

83 e Fatty Acid Sensor (FAS) Study received 5 g fish oil/d, containing 1.9-2.2 g eicosapentaenoic acid a

84 aculture relies heavily on the fish meal and fish oils derived from capture fisheries, challenging su

85 We evaluated the efficacy of fish oil-derived n-3 (omega-3) PUFA therapy to slow the

86 Fish oil-derived n-3 PUFA therapy slows the normal decli

87 While fish oil did not induce oxidative acceleration, querceti

88 educed in whey-sensitized donor mice fed the fish oil diet as compared to the control diet.

89 eOuJ female donor mice were fed a control or fish oil diet before and during oral sensitization with

90 Fish oil diet up-regulated hepatic CAT (activity and exp

91 -sensitized donor mice fed either control or fish oil diet were adoptively transferred to naive recip

92 An omega-3 PUFA-enriched HFD (referred to as fish oil diet, FOD) reduced inflammation in the obese ma

93 groups and received control, flaxseed oil or fish oil diets (10%w/w).

94 High-dose fish oil does not reduce AF recurrence in patients with

95 Furthermore, fish oil does not reduce inflammation or oxidative stres

96 Fish oil during early postnatal period may modulate the

97 repared with milk fat, soya bean oil or tuna fish oil during in vitro digestion with pancreatic lipas

98 bility to enteric damage and the benefits of fish oil during infection.

99 tion to obesity, maternal intake of DHA-rich fish oil during the second half of pregnancy does not af

100 women who were randomly assigned to receive fish oil during the third trimester of pregnancy, olive

101 sules from double (DM) and multilayered (MM) fish oil emulsions were produced to evaluate the effect

102 ased more slowly than other fatty acids from fish oil emulsions.

103 In fish oil-emulsions, all esters were more effective than

104 ponent to enhance the oxidative stability of fish oil encapsulated in alginate-chitosan beads.

105 l characteristics and oxidative stability of fish oil encapsulated in filled hydrogel particles was d

106 s in stabilising capsule wall and protecting fish oil encapsulates from heat induced disruption and o

107 Fish oil encapsulates stabilised with gum arabic and sag

108 d caffeic acid was assessed in two different fish oil enriched food products: mayonnaise and milk.

109 Fish oil enriched mayonnaise with caffeates of medium al

110 Whereas in fish oil enriched milk emulsions the most effective caff

111 Feeding mice a fish oil-enriched diet completely restored hepatic Sort1

112 This suggests that fish oil-enriched diets disfavor AA oxygenation by alter

113 end, the following steps were conducted: (i) fish oil extraction, (ii) Omega-3 free fatty acids (FFA)

114 we observe that C-22 FAs, including omega-3 fish oil FAs, have higher affinities for Ecat than Eallo

115 brown adipocytes, similar to cold-exposed or fish oil-fed brown fat.

116 nd brown thermogenesis was also confirmed in fish oil-fed C57/BL6 mice.

117 By contrast, splenocytes of fish-oil-fed whey-sensitized - but not sham-sensitized -

118 Feeding fish a fish oil finishing diet (FOFD) after grow-out on vegetab

119 C, or high-oleic sunflower seed oil HOSO, or fish oil FO) during simulated gastrointestinal digestion

120 wth trial compared a control diet containing fish oil (FO) as the main lipid source and different VO-

121 OP has been added to conventional fish oil (FO) feed at 4% and this was the OP diet, havin

122 Fish oil (FO) has antiinflammatory effects, which might

123 Fish oil (FO) intravenous lipid emulsions (ILEs) are use

124 program gilthead seabream offspring through fish oil (FO) replacement by vegetable oils (VO) in the

125 Olive oil (OO) and fish oil (FO) supplements have beneficial effects on end

126 As a novelty, EPA, DHA or fish oil (FO) were incorporated as omega-fatty acid sour

127 The replacement of fish oil (FO) with a DHA-rich Schizochytrium sp. algal m

128 D patients were randomised to receive either fish oil (FO), flaxseed oil (FSO) or corn oil capsules (

129 level, AM was used to replace 50% or 100% of fish oil (FO), or without AM (FO control) and supplement

130 ) polyunsaturated fatty acids (LC-PUFA) from fish oil (FO), to compare with diets containing high lev

131 Fish oil (FO)-derived eicosapentaenoic acid (EPA) modula

132 lly limited marine ingredients, fishmeal and fish oil (FO).

133 rmulated: diet 1 (control) consisted of only fish oil (FO); diets 2 and 3 had increasing amounts of a

134 in polyunsaturated fatty acids [contained in fish oil (FO)] and folate, are important in achieving no

135 and 50% SO], MSF (50% MCTs, 40% SO, and 10% fish oil (FO)], OS (80% olive oil and 20% SO), or MOSF (

136 nted (2.8% wt:wt) with corn oil (CO; n-6) or fish oil (FO; n-3) for 28 d.

137 Parenteral fish-oil (FO) therapy is a safe and effective treatment

138 Recent trials of fish oil for the prevention of atrial fibrillation (AF)

139 s on the website for Vascepa, a prescription fish oil for which Food and Drug Administration speciall

140 ospholipid (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED).

141 g powder products that are easy-to-use solid fish oil formulation, which makes the handling and stora

142 Fish oils (FOs) have anti-inflammatory effects and lower

143 lipid emulsion containing 10% fish oil or a fish oil-free lipid emulsion.

144 the potential to prevent PUFA in linseed or fish oil from ruminal biohydrogenation and oxidation dur

145 ts, suitable qualities to adequately replace fish oil from the perspective of fish performance and fi

146 , the rate of graft failure was lower in the fish oil group (3.43 vs 5.95 per 1000 access-days; incid

147 prescribed was significantly reduced in the fish oil group compared with the olive oil group (hazard

148 edication prescribed was also reduced in the fish oil group compared with the olive oil group (hazard

149 in the olive oil group, and 19 (4.9%) in the fish oil group.

150 the following order: corn oil approximately fish oil > orange oil > mineral oil > MCT.

151 triglycerides (MCT) > corn oil approximately fish oil > orange oil > mineral oil.

152 parenteral nutrition, patients who received fish oil had a faster time to ICU discharge alive (hazar

153 age, yogurt fortified with nano-encapsulated fish oil had a higher DHA and EPA contents than yogurt c

154 bean oil, patients who received olive oil or fish oil had a shorter time to termination of mechanical

155 High-dose fish oil has been explored in two randomised trials in d

156 Fish oil has been identified as one of the most importan

157 Omega-3 fatty acids from fish oil have been associated with beneficial cardiovasc

158 lability of polyunsaturated fatty acids rich fish oil have been investigated via three-step experimen

159 Fish oils have many dietary benefits, but due to their s

160 -3 polyunsaturated fatty acids (contained in fish oil) have been shown to beneficially influence infe

161 r an HFD supplemented with 3% n-3 PUFAs from fish oil (HFD + FO) for 8 wk.

162 iers (NLC) containing tristearin and omega-3 fish oil, (ii) tristearin solid lipid nanoparticles (SLN

163 Fish oil improves cardiometabolic markers in adults, but

164 However, increasing concentration of fish oil in a membrane might increase the acyl chain dyn

165 creasingly provided by aquaculture but using fish oil in feeds to supply n-3 LC-PUFA is unsustainable

166 ed crossover trial of low-dose and high-dose fish oil in participants with drug resistant epilepsy to

167 uce an oil containing n-3 LC-PUFA to replace fish oil in salmon feeds.

168 d emulsions are more suitable to encapsulate fish oil in terms of quantity of encapsulated oil, micro

169 Oxidation of fish oil in the sorghum wax oleogels were delayed consid

170 , nano-liposome was used to nano-encapsulate fish oil in this study and encapsulated fish oil was uti

171 o delay iron catalyzed lipid oxidation in 5% fish oil in water emulsions and the 10-50kDa fraction wa

172 rst study on the nanoencapsulation of Danube fish oils in beta-cyclodextrin.

173 ybean, medium-chain triglyceride, olive, and fish oils in parenteral nutrition were compared using an

174 onal finite marine ingredients, fishmeal and fish oil, in farmed salmon diets with sustainable altern

175 Fish oil-in-water emulsions (20% v/v) were exposed to ir

176 reasing lipophilicity has been determined in fish oil-in-water emulsions and nanoemulsions by the pse

177 id oxidation and protein partitioning in 10% fish oil-in-water emulsions prepared with different whey

178 of high-fat omega-3 delivery systems such as fish oil-in-water emulsions stabilized with combinations

179 e and optical properties on the stability of fish oil-in-water emulsions to riboflavin-induced oxidat

180 lipid nanoparticles (SLN), and (iii) omega-3 fish oil-in-water emulsions was investigated.

181 and glycosylated alkyl gallates (C4-C18) on fish oil-in-water emulsions was studied.

182 nd oxidative stabilization of 5% (by weight) fish oil-in-water emulsions were investigated.

183 ers for the production of oxidatively stable fish oil-in-water emulsions.

184 idation in liposome model system), and in 5% fish oil-in-water emulsions.

185 the physical and oxidative stability of 70% fish oil-in-water emulsions.

186 This study shows that fish oil-in-water nanoemulsions can be formed from sunfl

187 Twelve arsenolipids were identified in the fish oil including three AsFAs and seven AsHCs.

188 evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress in patients

189 tabolite CMPF was the strongest biomarker of fish oil intake.

190 s of human randomized controlled trials with fish-oil intervention during pregnancy and lactation gav

191 ls by aerogels was evaluated through loading fish oil into the non-blended aerogel.

192 tudy indicates that adding nano-encapsulated fish oil into yogurt gave closer characteristics to cont

193 f polycyclic aromatic hydrocarbons (PAHs) in fish oils is complicated due to the fat matrix, which af

194 A), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory

195 lowered with loading, which is mainly due to fish oil leakage.

196 rium partition data for diverse chemicals in fish oil, linseed oil, and goose fat at 37 degrees C.

197 replacing the soybean oil with a parenteral fish-oil lipid emulsion or emulsions of mixed-lipid sour

198 ygen permeability and oxidative stability of fish oil-loaded electrosprayed capsules were studied by

199 fish oil concentration, melting point of the fish oil-loaded particles shifted to lower onset melting

200 The highest fish oil loading efficiency (97.5%, w/w) was achieved at

201 soybean oil; 2.9% of DM) or FO (n = 5 cows; fish oil manufactured from salmon oil; 2.9% of DM).

202 Fish oil markedly enhanced EPA and DHA in mouse skin wit

203 The results indicate that low-dose fish oil may reduce seizures and improve the health of p

204 enrichment and bioaccessibility, the type of fish oil microcapsules may be selected as a function of

205 on of monolayered (MO) and multilayered (MU) fish oil microcapsules to meat model systems and determi

206 The type of fish oil microcapsules, the processing and/or culinary c

207 Maternal supplementation with fish oil might have prophylactic potential for long-term

208 yunsaturated fatty acids (PUFAs), present in fish oils, modulate channel inactivation.

209 rge multicentre randomised trial of low-dose fish oil (n-3 fatty acids <1080 mg/day) in drug resistan

210 and hen egg yolk (HL) lecithin in sunflower-fish oil O/W emulsion systems.

211 tors, including vitamin B12, folic acid, and fish oil; obesity; and stress.

212 y was to evaluate the influence of high-dose fish oil on AF recurrence, inflammation, and oxidative s

213 eneficial effects of dietary flaxseed oil or fish oil on streptozotocin-nicotinamide induced diabetic

214 The effect of dietary fish oil on weight gain and insulin sensitivity is depen

215 polyunsaturated fatty acids, commonly called fish oils) on the occurrence of clinical cardiovascular

216 lipids--vitamin A, beta-carotene and omega-3 fish oil--on the structural arrangement of solid lipid n

217 either with a lipid emulsion containing 10% fish oil or a fish oil-free lipid emulsion.

218 oad; the main exclusions were regular use of fish oil or absence of sinus rhythm at enrollment.

219 Nutritional supplementation with fish oil or omega-3 (n-3) polyunsaturated fatty acids (P

220 itamin D3 (2000 IU/d of cholecalciferol) and fish oil or placebo; 9181 were randomized to vitamin D3

221 of gestation to receive 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day.

222 igned to receive 2000 IU vitamin D3, 1000 mg fish oil, or placebo daily for 6 mo.

223 The flavonol-rich fractions inhibited fish oil oxidation by 40-62% at a total phenolic concent

224 ated oleogel had the best protection against fish oil oxidation under both thermal treatment and ultr

225 Inhibition of fish oil oxidation was studied using the thiobarbituric

226 significantly increased compared to the free fish oil (p<0.05).

227 l load on the oxidation of microencapsulated fish oil powders was investigated.

228 Forty-seven fish oil products available on the New Zealand market we

229 stark contrast to the very low percentage of fish oil products reported to be in compliance with prim

230 infections was significantly reduced in the fish oil-receiving group (21.0% vs 37.2%, p = 0.035) and

231 The effect of fish oil recovered from fish visceral waste (FVW-FO) on

232 e supports that omega-3 dietary fatty acids (fish oil) reduce the risks of macular degeneration and c

233 Results indicated that the presence of fish oil reduced the crystallisation temperature, meltin

234 psy to explore whether low-dose or high-dose fish oil reduces seizures or improves cardiovascular hea

235 Supplementation with fish oil resulted in about half of the VAS pain reductio

236 ch in saturated fatty acids) with or without fish oil (rich in n-3 PUFAs).

237 Dietary fish oils, rich in long-chain n-3 (omega-3) fatty acids

238 someric abundances of EPA and DHA in several fish oil samples.

239 samples of animal origin as shell powder and fish oil showed the highest concentrations of 56 and 29

240 1 transgenic mice and oral administration of fish oil, significantly promote interstitial Abeta clear

241 -chain triglycerides, 25% olive oil, and 15% fish oil (SMOF) with that of soybean oil (SO)-based lipi

242 We evaluated the influence of a fish-oil supplement over 5 mo on the kinetics of (13)C-D

243 acids." In multivariable-adjusted analyses, fish oil supplementation and fatty cold water fish intak

244 Although it has been shown that fish oil supplementation enhances EPA (eicosapentaenoic

245 Fish oil supplementation had no statistically significan

246 with lower CVD risk, although the effects of fish oil supplementation remains inconsistent.

247 the plasma triglyceride concentration after fish-oil supplementation compared with placebo treatment

248 o of omega-6-to-omega-3 PUFA through diet or fish-oil supplementation during pregnancy.

249 Fish-oil supplementation increased numbers of EPCs and r

250 There was no significant effect of fish-oil supplementation on blood pressure, plasma lipid

251 We investigated effects of fish-oil supplementation on both classical and novel mar

252 contrast, there was a significant effect of fish-oil supplementation on cellular markers of endothel

253 Effects of genotype and fish-oil supplementation on the blood lipid profile, inf

254 Fish-oil supplementation successfully increased plasma n

255 al function, which indicated that effects of fish-oil supplementation were independent of eNOS genoty

256 cal study suggested that omega-3 fatty acid (fish oil) supplementation blunted cardiac responses to a

257 Importantly, switching to a fish oil-supplemented diet induced a recovery in DHA con

258 60 weeks, when frogs were then switched to a fish oil-supplemented diet.

259 sh contain DHA in phospholipid form, whereas fish oil supplements do not.

260 ontent by a recently published assessment of fish oil supplements in New Zealand.

261 12% to 17%], P for trend < .001) and use of fish oil supplements increased from 1.3% to 12% (differe

262 Similar analyses for prenatal fish oil supplements showed no such association with aut

263 3 groups: placebo (olive oil), krill oil, or fish oil supplements.

264 in 3%); epistaxis associated with the use of fish-oil supplements (in 3%); and atrial fibrillation as

265 rivatives of p-hydroxybenzoic acid in a bulk fish oil system and its O/W emulsion were investigated.

266 However, the amount of fish oils that would have to be consumed to sustain chro

267 ietary supplementation with omega-3/6 PUFAs (fish oils) that have emerged from epidemiological studie

268 Upon oxidation of the fish oil, the dimethyl furan fatty acids degraded faster

269 determined if enriching the maternal diet in fish oil, the primary source of EPA and DHA, affected ad

270 cids, and tocopherols in an enriched omega-3 fish oil to better understand their degradation kinetics

271 e significantly decreased when the amount of fish oil, total emulsifier and ratio of CAS to PC were i

272 sted to concentrate omega-3 fatty acids from fish oils, under mild enzymatic conditions.

273 ociation with autistic disorder, even though fish oil use was associated with the same maternal chara

274 sing delivery emulsions (DEs) containing 70% fish oil versus neat fish oil was investigated.

275 o-controlled trial of low-dose and high-dose fish oil versus placebo (corn oil, linoleic acid) in 24

276 CRP, 11% vs. -11%; DeltaMPO, -5% vs. -9% for fish oil vs. placebo, respectively; p value for interact

277 Low-dose fish oil was also associated with a mild but significant

278 hase II randomised crossover trial, low-dose fish oil was effective in reducing seizures compared wit

279 Fish oil was encapsulated in hollow solid lipid micro- a

280 ctiveness in retarding lipid peroxidation in fish oil was evaluated by an accelerated stability test.

281 The oxidation of fish oil was inhibited by 2-3 fold, compared to its unen

282 olysates (FPH) for the microencapsulation of fish oil was investigated.

283 l-in-water (O/W) emulsions containing 20%v/v fish oil was investigated.

284 ns (DEs) containing 70% fish oil versus neat fish oil was investigated.

285 Fish oil was loaded into the microcapsule core and prote

286 High-dose fish oil was no different than placebo in reducing seizu

287 The results showed that the fish oil was rich in monomethyl and dimethyl furan fatty

288 Oxidative stability of the loaded fish oil was significantly increased compared to the fre

289 late fish oil in this study and encapsulated fish oil was utilized in fortifying yogurt.

290 parenteral nutrition, particularly olive and fish oil, was associated with improved clinical outcomes

291 ructure of gelatin and its adsorption at the fish-oil/water interface and to quantify the implication

292 nce on membrane fluidity, when quercetin and fish oil were encapsulated.

293 ared using long chain triglycerides (corn or fish oil) were most effective at increasing vitamin bioa

294 roup were given a typical diet containing 3% fish oil, whereas other groups were given the same diet

295 ega-3 LC-PUFA to serve as an alternative for fish oil, which was used as the 'golden standard'.

296 It has been previously reported that dietary fish oils, which are rich in the polyunsaturated fatty a

297 s were delayed considerably compared to free fish oil, while SDW generated the most stable oleogels.

298 toward eliminating reliance on fishmeal and fish oil with evidence of a cost-competitive microalgae-

299 Furthermore, substitution of fish oil with vegetable oil and fish meal with plant see

300 Replacement of fish oil with vegetable oil reduced formation of primary